Stryker Corp  (SYK)
Other Ticker:  
Price: $235.3008 $2.03 0.871%
Day's High: $234.78 Week Perf: 3.42 %
Day's Low: $ 231.47 30 Day Perf: -10.09 %
Volume (M): 87 52 Wk High: $ 281.16
Volume (M$): $ 20,286 52 Wk Avg: $260.70
Open: $231.71 52 Wk Low: $224.02

 Market Capitalization (Millions $) 90,050
 Shares Outstanding (Millions) 383
 Employees 43,000
 Revenues (TTM) (Millions $) 17,430
 Net Income (TTM) (Millions $) 2,015
 Cash Flow (TTM) (Millions $) -780
 Capital Exp. (TTM) (Millions $) 561

Stryker Corp
Stryker Corporation is a leader in the worldwide orthopaedic market and is one of the world's largest medical device companies. Stryker delivers results through a wide range of capabilities including joint replacements, trauma, spine and micro implant systems, orthobiologics, powered surgical instruments, surgical navigation systems and endoscopic products as well as patient handling and emergency medical equipment. Stryker also provides outpatient physical therapy services in the United States. Stryker was incorporated in Michigan in 1946 as the successor company to a business founded in 1941 by Dr. Homer H. Stryker, a leading orthopaedic surgeon and the inventor of several orthopaedic products.

The Company segregates its operations into two reportable business segments: Orthopaedic Implants and MedSurg Equipment. The Orthopaedic Implants segment sells orthopaedic reconstructive (hip, knee and shoulder), trauma and spinal implants, bone cement and the bone growth factor osteogenic protein-1 ("OP-1").  The MedSurg Equipment segment sells powered surgical instruments, endoscopic products, hospital beds and stretchers and micro implant and surgical navigation systems. 

Most of the Company's products and product improvements have been developed internally. The Company maintains close working relationships with physicians and medical personnel in hospitals and universities who assist in product research and development. New and improved products play a critical role in the Company's sales growth. The Company continues to place emphasis on the development of proprietary products and product improvements to complement and expand its existing product lines. The Company has a decentralized research and development focus, with manufacturing locations responsible for new product development and product improvements. Research, development and engineering functions at the manufacturing locations maintain relationships with distribution locations and customers to understand changes in the market and product needs.

In the United States, most of the Company's products are marketed directly to more than 6,000 hospitals and to other health-care facilities and doctors by approximately 2,100 sales and marketing personnel. Stryker primarily maintains separate and dedicated sales forces for each of its principal product lines to provide focus and a high level of expertise to each medical specialty served.

The Company's manufacturing processes consist primarily of precision machining, metal fabrication and assembly operations; the forging and investment casting of cobalt chrome; and the finishing of cobalt chrome and titanium. In addition, the Company is the sole manufacturer of its OP-1 product. The principal raw materials used by the Company are stainless steel, aluminum, cobalt chrome and titanium alloys. 


The Company is one of four leading competitors in the United States for orthopaedic reconstructive products. The three other leading competitors are DePuy Orthopaedics, Inc. (a subsidiary of Johnson & Johnson), Zimmer Holdings, Inc., and Biomet, Inc. While competition abroad varies from area to area, the Company believes it is also a leading player in the international markets with these same companies as its principal competitors.

In the trauma implant segment, Stryker is one of five leaders competing principally with Synthes-Stratec, Smith & Nephew Orthopaedics (a division of Smith & Nephew plc), Zimmer Holdings, Inc., and DePuy Orthopaedics, Inc.

In the spinal implant segment, the Company is one of four leaders, including the principal competitors Medtronic SofamorDanek, Inc. (a subsidiary of Medtronic, Inc.), DePuyAcroMed, Inc. (a subsidiary of Johnson & Johnson), and Synthes-Stratec.

The Company believes that several companies are engaged in the research and development of morphogenic proteins for the repair of hard and soft tissues that would compete with the Company's OP-1 product. Wyeth has completed human clinical trials of a recombinant bone morphogenetic protein ("rhBMP-2") for repair of orthopaedic and other skeletal defects and has awarded certain distribution rights to Medtronic SofamorDanek for rhBMP-2 in the United States and Europe. A number of companies currently provide various other therapies, including allografts, bone fillers and electrical stimulation devices for the treatment, repair or replacement of bone and joint tissue. The Company believes that its OP-1 product, which is approved for limited trauma indications in certain markets and is currently in clinical trials for other indications, would ultimately compete with these products and with traditional therapies, such as autograft.

In the powered surgical instruments segment, Stryker is one of three leaders, together with the principal domestic competitors Medtronic Midas Rex, Inc. (a subsidiary of Medtronic, Inc.), and Linvatec, Inc. (a subsidiary of CONMED Corporation).  These companies are also competitors in the international segments, along with Aesculap-Werke AG (a division of B. Braun Melsungen AG), a large European manufacturer.

In the arthroscopy segment, the Company is one of four leaders, together with the principal competitors Smith & Nephew Endoscopy (a division of Smith & Nephew plc), Linvatec, Inc., and Arthrex, Inc. In the laparoscopic imaging products segment, the Company is one of four leaders, together with the principal competitors Karl Storz GmbH & Co. (a German company), ACMI Corporation and Olympus Optical Co. Ltd. (a Japanese company).

In the craniomaxillofacial segment, Stryker is one of four leaders, together with the principal competitors Synthes-Stratec, Walter Lorenz Surgical, Inc. (a subsidiary of Biomet, Inc.), and KLS Martin L.P.

In the surgical navigation segment, Stryker is one of five principal competitors including Medtronic Surgical Navigation Technologies (a division of Medtronic, Inc.), BrainLAB Inc. (a subsidiary of BrainLAB AG), AESCULAP AG & Co. KG (a division of B. Braun Melsungen AG), Radionics, Inc. (a subsidiary of Tyco International Ltd.), and GE Medical Systems Navigation and Visualization, Inc. (a subsidiary of General Electric Company).

The Company's primary competitor in the patient-handling segment is Hill-Rom Company, Inc. (a division of Hillenbrand Industries, Inc.). In the specialty stretcher segment, the primary competitors are Hausted, Inc. (a subsidiary of STERIS Corporation), Hill-Rom Company, Inc., and Midmark Hospital Products Group (a subsidiary of Ohio Medical Instrument Company, Inc.). In the ambulance cot segment, Ferno-Washington, Inc. is the Company's principal competitor.

In the United States outpatient physical and occupational rehabilitation segment, the Company's primary competitors are independent therapist-owned practices and hospital-based services, in addition to other national rehabilitation companies, including HEALTHSOUTH Corporation and NovaCare Rehabilitation (a division of Select Medical Corporation).

The principal factors that the Company believes differentiate it in these highly competitive market segments and enable it to compete effectively are innovation, reliability, service and reputation. The Company is not able to predict the effect that continuing efforts to reduce health-care expenses generally and hospital costs in particular will have on the future sales of its products or its competitive position. The Company believes that its competitive position in the future will depend to a large degree on its ability to develop new products and make improvements in existing products. While the Company does not consider patents a major factor in its overall competitive success, patents and trademarks are significant to the extent that a product or attribute of a product represents a unique design or process. Patent or trademark protection of such products restricts competitors from duplicating these unique designs and features. Stryker seeks to obtain patent protection on its products whenever possible. The Company currently has approximately 840 United States patents and 1,240 international patents.

   Company Address: 2825 Airview Boulevard Kalamazoo, 49002 MI
   Company Phone Number: 385-2600   Stock Exchange / Ticker: NYSE SYK
   SYK is expected to report next financial results on July 27, 2022.

Customers Net Income fell by SYK's Customers Net Profit Margin fell to

-62.45 %

0.81 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
BSX        4% 
MCK        0.92% 
CAH   -1.45%    
DHR        3.84% 
JNJ   -0.2%    
• View Complete Report

360 Digitech Inc

Outstanding EPS Increase by 360 Digitech Inc in the fourth quarter of 2021 announcement

360 Digitech Inc showed respectable growth in the fourth quarter of 2021, where earnings jumped by 61.14 % year on year to $2.82 per share and Sales increased by 25.58% to $2.61 billions.

Galapagos Nv

Logged a Loss by Galapagos Nv in the fourth quarter of 2021 release

In the fourth quarter of 2021 Galapagos Nv lost money of $-1.77 per share compared to $-5.25 a year ago and from $0.00 per share from the previous quarter.

Canadian Solar inc

Canadian Solar Inc disclosed Sales almost doubled in the fourth quarter of 2021 earnings season

Canadian Solar Inc announced earnings per share of $1.46 and Sales of $0.00 millions in the fourth quarter of 2021 earnings season, Company's income dropped by -38.66 % per share, versus $2.38 eps, earned in the same quarter a year ago, although Canadian Solar Inc saw its Sales rise by 51.8% in the same period.

Flex Lng Ltd

Flex Lng Ltd reported that company went from strength to strength in the financial fourth quarter of 2021

Flex Lng Ltd has more than doubled its results in the financial fourth quarter of 2021 compared to same quarter a year ago, earnings per share soared by 1926.67 % to $3.04 and Sales soared by 108.83% to $343.45 millions.

North American Construction Group Ltd.

North American Construction Group Ltd disclosed a same Sales like a year ago in the financial period ending Dec 31 2019

In the financial period ending Dec 31 2019 North American Construction Group Ltd income surged by 74.48 % of $0.94 per share compared to $0.54 a year ago and from $0.00 per share from the previous quarter.


Stryker's Segments
 Segment    12.69 % of total Revenue
 Segment    13.72 % of total Revenue
Trauma & Extremities
 Segment    13.14 % of total Revenue
Total Reconstructive
 Segment    42.11 % of total Revenue
Surgical equipment
 Segment    14.83 % of total Revenue
Endoscopic & communications systems
 Segment    13.88 % of total Revenue
Patient handling & emergency equipment
 Segment    8.06 % of total Revenue
Total MedSurg
 Segment    38.97 % of total Revenue
 Segment    7.56 % of total Revenue
 Segment    11.36 % of total Revenue
Total Neurotechnology & Spine
 Segment    18.93 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Stryker does not provide revenue guidance.

Earnings Outlook
North American Construction Group Ltd. does not provide earnings estimates.

Geographic Revenue Dispersion
United States 67.78 %
Asia Pacific 14.14 %
Europe 14.17 %
Other 3.91 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

ODZA's Profile

Stock Price

ODZA's Financials

Business Description


Charts & Quotes

ODZA's News


ODZA's Competitors

Customers & Markets

Economic Indicators

ODZA's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071